Form 4: BioXcel Therapeutics CEO Vimal Mehta Reports Stock Sales and Transfers

Vimal Mehta, CEO of BioXcel Therapeutics, reports multiple transactions involving the transfer and sale of common stock, including indirect holdings through BioXcel LLC and BioXcel Holdings, Inc.

Summary

• Vimal Mehta, CEO of BioXcel Therapeutics, along with BioXcel Holdings, Inc. and BioXcel LLC, filed a Form 4 detailing changes in beneficial ownership.
• On June 4, 2024, BioXcel LLC transferred 566,245 shares of common stock to its parent company and 42,976 shares to other members in exchange for common interests in BioXcel LLC.
• Subsequently, the parent company transferred 566,245 shares to its stockholders for their interests in the parent company.
• Mehta also reported the sale of shares to cover certain tax liabilities, with 126,014 shares sold on both June 4 and June 5, 2024, at weighted average prices of $1.6309 and $1.5841, respectively.
• These transactions resulted in changes to the number of shares beneficially owned indirectly by Mehta through BioXcel LLC and BioXcel Holdings, Inc.
• Mehta also reported transactions involving call options related to common interests in BioXcel LLC.

Sentiment

Score: 5

Explanation: This is a neutral regulatory filing. It reports transactions but doesn't inherently indicate positive or negative sentiment about the company's prospects.

Management Comments

• Vimal Mehta, Ph.D. is an executive officer and the sole member of the board of directors of Parent and an executive officer and one of two managers on the board of managers of BioXcel LLC.
• Each disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.
• This report shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose.

Industry Context

Form 4 filings are standard practice for company insiders to report transactions in their company's stock, providing transparency to investors.

Comparison to Industry Standards

• Form 4 filings are a standard regulatory requirement for corporate insiders in the US, ensuring transparency in stock transactions.
• Similar filings are made by executives at comparable pharmaceutical companies like Eli Lilly, Pfizer, and Johnson & Johnson, whenever they buy or sell shares of their respective companies.
• The level of detail provided in this Form 4 is consistent with industry norms, including the number of shares, transaction dates, and prices.

Stakeholder Impact

• The reported stock sales may have a minor impact on shareholder sentiment, depending on how investors interpret the insider transactions.
• The transactions do not appear to directly impact employees, customers, suppliers, or creditors.

Key Dates

Keywords

BioXcel Therapeutics, Vimal Mehta, Form 4, Beneficial Ownership, Stock Sales, Stock Transfers, BioXcel LLC, BioXcel Holdings, CEO, BTAI